Lung cancer: current therapies and new targeted treatments

  title={Lung cancer: current therapies and new targeted treatments},
  author={Fred R. Hirsch and Giorgio Vittorio Scagliotti and James L. Mulshine and Regina Kwon and Walter J Curran and Yi-Long Wu and Luis Paz-Ares},
  journal={The Lancet},

Tables from this paper

Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments

Cardio-oncology is a new interdisciplinary collaboration to develop methodologies to manage cardiovascular risk factors and CTRCDs with the common goal of minimizing unnecessary interruption of cancer treatment and maximizing outcomes of lung cancer survivors.

Molecular Pathology of Primary Non-small Cell Lung Cancer.

Subgroup Discovery Analysis of Treatment Patterns in Lung Cancer Patients

A dataset containing lung cancer patients information including patients' data, prescribed treatments and outcomes obtained is analyzed using a Subgroup Discovery method to identify patterns based on cancer stage while relying on treatment outcomes.

A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed

A small molecule dual-targeting broad-spectrum anticancer strategy called OncoCiDia is proposed, in combination with emerging highly sensitive liquid biopsy, with theoretical curative potential for the management of solid malignancies, especially at the micro-cancer stage.

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer

The recent SCLC studies of CTCs, cfDNA and other liquid biopsy biomarkers are summarized, the future utility of liquid biopsies in the clinical management of SCLCs is discussed, and the non-invasive, rapid, repeated and alternative tool to the traditional tumor biopsy is discussed.

Cell death-based treatment of lung adenocarcinoma

Recent advances in understanding the molecular pathways driving tumor progression and related targeted therapies in lung ADCs are discussed and the cell death mechanisms induced by different treatment strategies and their contribution to therapy resistance are analyzed.

Emerging Vaccine Immunotherapy In NSCLC: The Adverse Reactions of Recent Clinical Trials and Future Directions

The mechanisms of cancer vaccines for non-small cell lung cancer and a review of recent vaccine immunotherapy for lung cancer are focused on and some clinical adverse reactions are discussed, in order to provide a reference for vaccine Immunotherapy in the future.

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly

The most relevant and recent literature defining the role of chemotherapy, targeted therapy, and immunotherapy in the first-line treatment of elderly patients with metastatic NSCLC is reported and analysed.

Treatment patterns in non-small-cell lung cancer in USA: results of the CancerMPact Survey 2018.

The treatment choices of non-small-cell lung cancer are increasingly complex, involve different treatment modalities and are highly dependent on histology and biomarkers, besides stage.



Lung cancer: New biological insights and recent therapeutic advances

The major strides made in the treatment of lung cancer in the recent past have been made possible by developing a greater understanding of the biology, the discovery of novel anticancer agents, and improved supportive care measures.

Scientific Advances in Lung Cancer 2015

  • A. TsaoG. Scagliotti H. Pass
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2016

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

Recent developments in lung cancer immunotherapy are discussed, reviewing recent findings from therapeutic vaccine studies and in particular the refinement of immunomodulation as a therapeutic strategy in this challenging disease is focused on.

Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?

Specific barriers and challenges inherent to SCLC research and care are summarized, including those that have limited progress in novel therapeutic development to date.

Recommendations on screening for lung cancer

Screening for lung cancer screening has been proposed as an adjunct to other methods for reducing the burden of lung cancer, including global tobacco control initiatives and interventions designed to encourage smoking cessation.

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

MET as a possible target for non-small-cell lung cancer.

  • A. SadiqR. Salgia
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
The biology of MET is summarized as well as its therapeutic inhibition in lung cancer, and a number of compounds against MET/HGF in clinical trials that have been shown to be active in lung cancers are reviewed.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

  • D. TanS. Yom F. Hirsch
  • Medicine, Biology
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2016

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.